**Chapter 6**

*Advances in the Molecular Understanding of Colorectal Cancer*

deficiency. The New England Journal of Medicine. 2015;**372**(26):2509-2520

[143] Emambux S et al. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opinion on Biological Therapy.

[144] Passardi A et al. Immune checkpoints as a target for colorectal cancer treatment. International Journal of Molecular Sciences. 2017;**18**(6).

[145] Abdelfatah E et al. Epigenetic therapy in gastrointestinal cancer: The right combination. Therapeutic Advances in Gastroenterology.

[146] Okada K et al. Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. Oncology Reports. 2016;**36**(4):1875-1885

[147] Shah MY et al. microRNA therapeutics in cancer—An emerging concept. eBioMedicine. 2016;**12**:34-42

[148] Klann TS et al. CRISPR-Cas9 epigenome editing enables highthroughput screening for functional regulatory elements in the human genome. Nature Biotechnology.

2018;**18**(5):561-573

Artical ID: 1324

2016;**9**(4):560-579

**106**

2017;**35**:561
